JPRN-UMIN000034543招募中未知
Phase I Dose-Escalation Study of Accelerated Hyperfractionation and Intensity-modulated Radiation Therapy in Patients with Locally Advanced Non Small Cell Lung Cancer - Phase I Dose-Escalation Study of AHF and IMRT in Patients with Locally Advanced NSCLC
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University0 个研究点目标入组 15 人开始时间: 2018年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy 2) Active infection requiring systemic therapy 3) With severe complications 4) History of serious drug allegies 5) Patients with unstable and uncontrollable diabetic mellitus, hypertension, kidney disease, liver disease. 6) Patients with intersitial pneumonia or pulmonary fibrosis detectable on chest radiography 7) Women during pregnancy or breast-feeding, or patients who wish pregnancy 8) Patients that physicians consider inappropriate for this study
研究者
相似试验
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
招募中
不适用
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.ACTRN12616000008426Suzhou NeuPharma Co., Ltd.35
招募中
1 期
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2JPRN-jRCT2031230637Jansen Valerie40
招募中
1 期
Study of PF-07248144 in Advanced or Metastatic Solid Tumorsocally Advanced or Metastatic ER+ HER2- Breast Cancer, CRPC, NSCLCJPRN-jRCT2031200246Kawai Norisuke186
终止
1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid TumorsCancerACTRN12617001181392INC Research Pty Ltd4